Results of The HPTN 035 Trial

A Step Forward for the Microbicide Field
February 9, 2009

Final results of the HPTN 035 trial were announced today at the CROI conference in Montreal and for the first time, a microbicide candidate has been shown to be at least partially effective in preventing HIV in women.  PRO2000 (0.5%), a naphthalene sulfonate polymer gel, is 30% effective in preventing HIV infection in women.  While not statistically significant, this result is an important step forward for the microbicide field. 

“We at CONRAD are very encouraged by this result and congratulate the study team on a job very well done,” said Dr. Henry Gabelnick, Executive Director of CONRAD. “We look forward to gaining additional insights from the Medical Research Council’s current Phase III trial of PRO2000 involving 9400 women in Africa.  Most importantly, we appreciate the dedication of the women who participate in all of our trials.   We owe every step of progress to the thousands of women who volunteer for the greater good.” 

The four year study, conducted by the Microbicide Trials Network (MTN) and supported by NIH, also tested a microbicide candidate called BufferGel which was shown to be safe, but not effective.  The two candidates were tested in 3099 women in South Africa, Malawi, Zambia, Zimbabwe and Philadelphia, PA.  The study consisted of four groups – one each using PRO2000, BufferGel, a placebo, and no gel.  A total of 194 women were infected with HIV - 36 in the PRO 2000 group, 54 in the BufferGel group, 51 in the placebo group and 53 in those who did not use gel.

For more information and the full press release, please go to:

1911 North Fort Myer Drive, Suite 900, Arlington, Virginia 22209   T: (703) 524-4744 |